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Background
The effectiveness of a preventive vaccine in controlling the
epidemic will be contingent on acceptability and access.
The objective of this systematic review was to synthesize
results from investigations of HIV vaccine acceptability to
assess: 1) rates of HIV vaccine acceptability and 2) factors
impacting HIV vaccine acceptability.
Methods
We used a comprehensive search strategy to locate rele-
vant articles across multiple electronic databases, includ-
ing Medline, AIDSLine, CINAHIL and EMBASE, with no
language or time restrictions. We included original quali-
tative or quantitative studies examining rates or correlates
of HIV vaccine acceptability. Two authors independently
assessed study quality and extracted data. We conducted
meta-analysis on studies reporting correlates or predictors
of HIV vaccine acceptability and calculated effect sizes for
each variable.
Results
Twenty-nine original studies (n = 11,477; 17 quantitative,
12 qualitative) were included, from North America (n =
24), Africa (n = 3), Central America (n = 1) and Asia (n =
1). HIV vaccine acceptability, reported in 19 studies,
ranged from 94.0 to 37.2 on a 100-point scale, with mean
acceptability = 65.6 (SD = 20.5). Mean acceptability was
74.5 (SD = 9.4) at high (80–95%) versus 39.4 (SD = 21.1)
at moderate (50%) efficacy (p < 0.001), reported concur-
rently in 10 studies. Twelve studies (n = 4,768) were
included in meta-analysis. HIV vaccine acceptability was
positively correlated with: efficacy (r = 0.35, p < 0.001),
perceived susceptibility to HIV (r = 0.26, p < 0.001), and
perceived vaccine benefits (r = 0.17, p < 0.05); and nega-
tively associated with: cost (r = -0.33, p < 0.05), not being
in a "risk group" (r = -0.32, p < 0.001), pragmatic obsta-
cles (r = -0.29, p < 0.05), fear of vaccines (r = -0.20, p <
0.05), side effects/safety concerns (r = -0.16, p < 0.01), fear
of needles (r = -0.12, p < 0.05), and African American eth-
nicity (r = -0.08, p < 0.05).
Conclusion
Findings support development of tailored educational,
social and structural interventions to promote uptake of
partially efficacious HIV vaccines. Cost subsidies and
measures to facilitate access and address vaccine fears, atti-
tudes and low HIV risk perceptions may support roll-out
of HIV vaccines.
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